Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology & Autoimmune Development
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for FOLR2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FOLR2 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1 EU/µg. HEK293 expressed (Native Glycosylation). Sequence Verified. |
View FOLR2 Products |
| Gene Delivery | FOLR2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. GPI-anchored expression preserved. |
View FOLR2 Products |
| Benchmark Ab | Anti-FOLR2 Benchmark Antibody (Sequence of Clinical Benchmarks) Recombinant positive control for binding assays. |
View FOLR2 Products |
| Validator | FOLR2 siRNA Set Sequence-specific knockdown for target verification. |
View FOLR2 Products |
| Counter-Screen | FOLR1 (FRα) ECD-Fc Protein 92% homology in binding domain. Critical for off-target liability screening. |
View FOLR1 Products |
| Related Target A | FOLR3 (FRγ) ECD-Fc Protein Secreted isoform detection. Monitors soluble receptor interference in serum assays. |
View FOLR3 Products |
| Related Target B | CSF1R (CD115) Synergistic target for Tumor-Associated Macrophage (TAM) depletion and combination therapy. |
View CSF1R Products |
| Related Target C | TREM2 Emerging myeloid checkpoint for combined immunosuppression reversal. |
View TREM2 Products |
| Related Target D | SLC19A1 (RFC1) Resistance bypass and compensatory folate uptake pathway. |
View SLC19A1 Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| FOLR1/FOLR2 Selectivity (92% binding domain homology) | Sequence-verified FOLR2 vs FOLR1 ECD proteins with distinct epitope confirmation by Mass Spec |
| Cross-species Cyno/Mouse Evaluation | Human/Cyno/Mouse FOLR2 ortholog proteins available with >95% purity, Endotoxin controlled |
| Conformational Epitope Preservation | HEK293 expressed (Native Glycosylation) to ensure accurate folding of GPI-anchored receptor domains |
| ADC Internalization Efficiency | High-purity ECD-Fc preserves native conformation for pH-dependent binding assays |
| M2 Macrophage Phenotyping & Cell-Based Assays | Lentivirus Premade Particles enable robust stable cell line generation (THP-1, K562, HEK293T) |
| False Positives in Flow Cytometry | Validated siRNA included for rigorous specificity checks and target knockdown verification |
Live FOLR2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Macrophage Targeting & Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for FOLR2 therapeutics is intensifying, with major players shifting focus from traditional tumor-antigen targeting to tumor microenvironment (TME) modulation and autoimmune disease intervention. FOLR2, a folate receptor beta selectively expressed on activated M2 macrophages in the TME and rheumatoid arthritis synovium, offers a unique "cell-specific delivery" window. The pipeline bifurcates: Oncology applications (ADCs, CAR-T) aim to deplete or reprogram immunosuppressive TAMs; Immunology applications (bispecifics like anti-TNF/FRβ) target inflammatory macrophages in autoimmune diseases. A somatic mutation in FOLR2 (breast cancer, VAR_036408) underscores potential relevance in patient stratification. First-generation therapies are advancing, with the next wave focusing on combination regimens with immune checkpoint inhibitors and refined resistance mechanisms involving macrophage repolarization.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Bayer/MorphoSys, ImmuneRx, Emerging Biotechs | Solid Tumors (TAM depletion), AML | Internalization Assay (Need high-purity ECD-Fc with native glycosylation) |
| Bispecific / TCE (e.g., CD3xFOLR2, TNF/FRβ) | AbbVie, Immuno-Oncology Innovators | Rheumatoid Arthritis, Solid Tumors, Refractory Cancers | Heterodimer Validation (Need cross-reactive Abs against human/cyno FRβ and lentivirus cell lines) |
| CAR-T | Academic/Translational Centers | Ovarian Cancer, Sarcoma, Hematologic Malignancies | Cell Surface Density Calibration (Need lentivirus stable lines for binding and internalization assays) |
| Monoclonal Antibody (naked) | Multiple Biotech | TME Immunomodulation, Inflammatory Diseases | Selectivity Assay (Need FOLR1 vs FOLR2 discrimination panel) |
| Radioligand / Small Molecule | Radiopharma Groups | Imaging, Oncology | Selectivity Assay (WT vs mutant proteins, homolog panel) |
Key Scientific Insights & Mutation Data
In addition to the reagent toolkit, researchers should note the somatic mutation reported in a breast cancer sample (UniProt VAR_036408) which may influence target engagement or resistance. Continuous monitoring of FOLR2 biology and patient stratification markers is essential for next-generation therapeutics.